# TRIALS FUNDED BY NATIONAL MS SOCIETY

**Updated August 2012**

**Abbreviations Key:**

AAN – American Academy of Neurology
ECTRIMS – European Committee of Treatment and Research in MS
IM – intramuscular, injected into muscle
IV – intravenous, injected into vein
PP - primary progressive
PR - progressive relapsing
RR - relapsing-remitting
SC – subcutaneous, injected under the skin
SP - secondary progressive

| AGENT | PURPOSE OF STUDY | INVESTI-GATOR | UNIVERSITY/ COMPANY | TYPE OF MS/ NUMBER OF SUBJECTS | LINK TO MORE INFORMATION |
|---|---|---|---|---|---|
| Aspirin | To improve fatigue | Dean M. Wingerchuk | Mayo Clinic, Scottsdale, AZ | RR, SP/ 135 | http://clinicaltrials.gov/ct2/show/NCT00467584. |
| ATX-MS-1467 | To assess safety and biological activity | David Wraith, PhD | Apitope Technology (Bristol), Ltd. | Relapsing/ 40 | http://clinicaltrials.gov/ct2/show/NCT01097668 |
| Cannabis extract (dronabinol vs. cannabis) | To improve spasticity | Mark Agius | University of California, Davis | SP, PP/ 60 | http://clinicaltrials.gov/ct2/show/NCT00682929 |

| AGENT | PURPOSE OF STUDY | INVESTI-GATOR | UNIVERSITY/ COMPANY | TYPE OF MS/ NUMBER OF SUBJECTS | LINK TO MORE INFORMATION |
|---|---|---|---|---|---|
| Estriol + glatiramer acetate (Copaxone®, Teva Pharmaceutical Industries, Ltd.) | To control disease course | Rhonda R. Voskuhl | University of California, Los Angeles | RR, Women/ 130 | http://clinicaltrials.gov/ct2/show/NCT00451204 |
| Helminth-induced immunomodulation therapy | To determine safety and effectiveness in reducing disease activity, also known as HINT 1 Study | May stimulate protective immune response | oral | RR/20 | Ongoing, read more http://clinicaltrials.gov/ct2/show/NCT01201707; in first phase, no significant adverse effects observed and favorable trends in MRI and immunological assessments (MS Journal 2011 Jun;17(6):743-54, http://www.ncbi.nlm.nih.gov/pubmed/21372112). |
| Hip flexion device | To improve gait | Francois A Bethoux | Cleveland Clinic Foundation, OH | All types/ 88 | Not available |
| Lipoic acid | To relieve optic nerve injury | Vijayshree Yadav | Oregon Health & Science University, Portland | optic neuritis/ 54 | http://clinicaltrials.gov/ct2/show/NCT01294176 |

| AGENT | PURPOSE OF STUDY | INVESTI-GATOR | UNIVERSITY/ COMPANY | TYPE OF MS/ NUMBER OF SUBJECTS | LINK TO MORE INFORMATION |
|---|---|---|---|---|---|
| Methylpred-nisolone | To compare oral versus intravenous delivery to control development of brain lesions and treat disease relapses, also known as OMEGA study | Teresa DeAngelis | Mount Sinai School of Medicine, New York | RR/ 140 | http://clinicaltrials.gov/ct2/show/NCT00418145. |
| Phenytoin | To prevent optic nerve injury | Raju Kapoor | University College, London, UK | optic neuritis/ 90 | http://clinicaltrials.gov/ct2/show/NCT01451593 |
| Progressive resistance training | To predict improve-ment in functional movement. | Kathleen Zackowski | Johns Hopkins University School of Medicine, Baltimore, MD | All types/ 60 | http://clinicaltrials.gov/ct2/show/NCT01632293 |
| Rehabilitation (resistance training) | To enhance smoking cessation | Joseph T Ciccolo | The Miriam Hospital, Providence, RI | RR/ 30 | Not available |
| Rehabilitation (aerobic exercise) | To improve cognitive function | Barbara S. Giesser | University of California, Los Angeles | All types/ 50 | http://clinicaltrials.gov/ct2/show/NCT01219647 |

| AGENT | PURPOSE OF STUDY | INVESTI-GATOR | UNIVERSITY/ COMPANY | TYPE OF MS/ NUMBER OF SUBJECTS | LINK TO MORE INFORMATION |
|---|---|---|---|---|---|
| Rehabilitation (constraint-induced movement therapy) | To rehabilitate extremity use | Victor Mark | University of Alabama at Birmingham | SP, PP/ 66 | http://clinicaltrials.gov/ct2/show/NCT01081275 |
| Rehabilitation (internet-based program to increase physical activity) | To increase physical activity | Robert Motl | University of Illinois at Urbana-Champaign | RR/ 50 | Not available |
| Rehabilitation (leg cycling) | To reduce spasticity | Jacob Sosnoff | University of Illinois at Urbana-Champaign | All types/ 30 | Not available |
| Rehabilitation (manualized cognitive rehabilitation program) | To improve memory and ability to perform activities | Michael Basso | University of Tulsa, OK | All types/ 20 | Not available |
| Rehabilitation (memory retraining) | To improve new learning and memory | Nancy Chiaravalloti | Kessler Foundation Research Center, West Orange, NJ | RR, progressive/ 200 | http://clinicaltrials.gov/ct2/show/NCT00166283. |

| AGENT | PURPOSE OF STUDY | INVESTI-GATOR | UNIVERSITY/ COMPANY | TYPE OF MS/ NUMBER OF SUBJECTS | LINK TO MORE INFORMATION |
|---|---|---|---|---|---|
| Rehabilitation (multi-modal exercise program vs. minimal exercise) | To reduce progression of mobility disability | Robert Motl | University of Illinois at Urbana-Champaign | All types/ 40 | Not available |
| Rehabilitation (telehealth self-management Intervention) | To manage fatigue and increase physical activity | Matthew Plow | Cleveland Clinic Foundation, OH | All types/ 215 | http://clinicaltrials.gov/ct2/show/NCT01572714 |
| Riluzole (Rilutek®, Sanofi) | To evaluate ability to protect nerves in MS | Emmanuelle Waubant | University of California, San Francisco | early MS, CIS/ 40 | http://clinicaltrials.gov/ct2/show/NCT00501943 |
| Vitamin D + glatiramer acetate (Copaxone®, Teva Pharmaceutical Industries, Ltd.) | To test safety and effective-ness in reducing disease activity | Ellen M. Mowry | Johns Hopkins University School of Medicine, Baltimore, MD | RR/ 172 | http://clinicaltrials.gov/ct2/show/NCT01490502 |